EphB2受体在结直肠癌发生发展中的表达

目的探讨EphB2受体在结直肠癌发生发展中的表达及其临床意义。方法应用免疫组织化学的方法检测24例正常肠黏膜组织、33例结直肠腺瘤性息肉组织、24例结直肠非典型增生组织、20例早期大肠癌组织、118例进展期结直肠癌组织中的EphB2受体的表达情况，并对进展期结直肠癌组织有无转移（转移组52例，未转移组66例）进行分组比较。结果（1）EphB2受体在正常肠黏膜、息肉、不典型增生、早期癌、进展期结直肠癌中的表达呈递减趋势，具有统计学差异；（2）EphB2受体在非转移性结直肠癌组织和转移性结直肠癌组织中的表达具有统计学差异（59．1％ vs. 40．4％，P=0．044）；（3）EphB2受体在不同分期的结直肠癌组织中的表达具有统计学差异（Duke’s A期、B期与Duke’s C期、D期比较）（60．0％ vs. 39．7％，P=0．018）；（4）EphB2受体在结直肠癌中的表达与年龄、性别、肿瘤大小、发生部位、分化程度、浸润深度等临床病理参数均无关。结论EphB2受体在结直肠癌的发生发展中可能起到了重要的抑制作用。

Expression of EphB2 receptor in the genesis and progression of colorectal tumors

Objective This research is to study the expression of EphB2 receptor in the genesis and progression of colorectal tumors. Methods Immunohistological staining was used to detect the expression of EphB2 in 24 normal colorectal mucosa, 33 adenomas, 24 atypical hyperplasia, 20 early carcinoma and 118 advanced tumors, and the different expressions of EphB2 among metastatic and non-metastatic CRC, including 52 metastatic cases and 66 non-metastatic cases were also under investigation. Results （ 1 ） Reduced expression of EphB2 receptor in the normal colorectal mucosa, adenomas, atypical hyperplasia, early carcinoma and advanced tumors ; （2）The expression of EphB2 receptor in the non-metastatic and metastatic advanced colorectal cancer was statistical different （ 59. 1% vs. 40.4% , P = 0. 044 ）. （ 3 ） The expression of EphB2 receptor in the different stages of colorectal cancer was statistical different （ Duke＇s A ＋ B compared with Duke＇s C ＋ D） （60.0% vs. 39.7% ,P =0. 018） ; （4）There was no relationship between the expression of EphB2 receptor and age, sex, tumor size, location, differentiation of malignancy and invasive depth. Condusions EphB2 receptor may play an important inhibitive role in the genesis and progression of colorectal tumors.